

## LISTING OF THE CLAIMS

1. - 10. (canceled).

11. (previously presented) A method for treating cancer in an animal in need thereof, the method comprising administering to the animal a composition comprising an extract of *Inula britannica* in an amount sufficient to induce phosphorylation of Bcl-2, such that the cancer is treated, wherein the extract comprises 1-*O*-acetylbritannilactone.

12. (previously presented) A method for treating cancer in an animal in need thereof, the method comprising administering to the animal a composition comprising an extract of *Inula britannica* in an amount sufficient to induce phosphorylation of Bcl-2, such that the cancer is treated, wherein the extract comprises 1,6-*O-O*-diacetylbritannilactone.

13. -14. (canceled).

15. (previously presented) The method of claim 11, wherein the animal is a human.

16. (previously presented) The method of claim 12, wherein the animal is a human.

17. (previously presented) The method of claim 15, wherein the cancer is ovarian cancer.

18. (previously presented) The method of claim 16, wherein the cancer is ovarian cancer.

19. (previously presented) The method of claim 15, wherein the cancer is prostate cancer.

20. (previously presented) The method of claim 16, wherein the cancer is prostate cancer.

21. (previously presented) The method of claim 15, wherein the cancer is breast cancer.

22. (previously presented) The method of claim 16, wherein the cancer is breast cancer.
23. (previously presented) The method of claim 15, wherein the composition is administered to the animal as a dietary supplement.
24. (previously presented) The method of claim 16, wherein the composition is administered to the animal as a dietary supplement.
25. (previously presented) The method of claim 17, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of PA-1 cells relative to a control.
26. (previously presented) The method of claim 18, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of PA-1 cells relative to a control.
27. (previously presented) The method of claim 25, wherein the concentration is about 2  $\mu\text{M}$ .
28. (previously presented) The method of claim 26, wherein the concentration is less than 7.815  $\mu\text{M}$ .
29. (previously presented) The method of claim 19, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of Du-145 cells relative to a control.
30. (previously presented) The method of claim 20, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of Du-145 cells relative to a control.
31. (previously presented) The method of claim 30, wherein the concentration is less than 15.6  $\mu\text{M}$ .
32. (previously presented) The method of claim 21, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of MCF-7 cells relative to a control.
33. (previously presented) The method of claim 22, wherein the amount produces at least a fifty percent (50%) decrease in cell viability of MCF-7 cells relative to a control.
34. (previously presented) The method of claim 32, wherein the concentration is about 200  $\mu\text{M}$ .

35. (previously presented) The method of claim 33, wherein the concentration is less than 12.5  $\mu\text{M}$ .

36. (previously presented) The method of claim 11 or 12, wherein the extract is prepared from the floral parts of *Inula britannica*.

37. (previously presented) The method of claim 11, wherein the extract further comprises 1,6-*O-O*-diacetylbritannilactone.

38. (previously presented) The method of claim 37, wherein the extract is a chloroform-soluble fraction of an *Inula britannica* var. *chinensis* ethanol extract.